Go To Main TNBC Website


  New Posts New Posts RSS Feed - Adding Carboplatin Increases PCR
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

Adding Carboplatin Increases PCR

 Post Reply Post Reply Page  12>
Author
123Donna View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 24 2009
Location: St. Louis, MO
Status: Offline
Points: 12573
Post Options Post Options   Thanks (1) Thanks(1)   Quote 123Donna Quote  Post ReplyReply Direct Link To This Post Topic: Adding Carboplatin Increases PCR
    Posted: Dec 13 2013 at 6:56pm

Additional drug shows promise for women with triple-negative breast cancer

 IMAGE: A new study suggests additional drug shows promise for women with triple-negative breast cancer.

Click here for more information.

SAN ANTONIO— In a nationwide study of women with "triple-negative" breast cancer, adding the chemotherapy drug carboplatin or the angiogenesis inhibitor Avastin to standard chemotherapy drugs brought a sharp increase in the number of patients whose tumors shrank away completely, investigators will report at the 2013 San Antonio Breast Cancer Symposium.

The results are especially promising in the case of carboplatin, study leaders say, as Avastin has shown little effectiveness as a long-term preventer of cancer recurrence. The study is scheduled to be presented Friday, December 13, at 9:30 a.m., CT.

"Our findings suggest that carboplatin could be used either in addition to or instead of some of the drugs in the standard chemotherapy regimen for women with triple-negative breast cancer," says the study's senior author, Eric Winer, MD, chief of the division of Women's Cancers in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute.

Triple-negative breast cancer, named for the lack of three growth-spurring receptors on its cells' surface, accounts for 15 to 25 percent of all breast cancer cases. Although it often goes into remission in response to chemotherapy, it can be more aggressive and more likely to recur than other breast cancers. Because of the dearth of three common receptors on the cell surface, triple-negative cancers usually aren't vulnerable to drugs that block these receptors in other types of breast cancer.

The current study involved 450 women with stage II or III triple-negative breast cancer. It was sponsored by the Cancer and Leukemia Group B, which is part of the Alliance for Clinical Trials in Oncology, a national clinical research network supported by the National Cancer Institute. As a pre-surgery treatment, the women were randomly assigned to receive either standard chemotherapy (a combination of paclitaxel, adriamycin, and cyclophosphamide), standard chemotherapy plus carboplatin, standard chemotherapy plus Avastin (a drug that blocks cancers from generating blood vessels), or standard chemotherapy plus both carboplatin and Avastin.

Among patients who received standard chemotherapy alone, 34 percent had their tumors disappear. That compares with 48 percent of patients in the chemotherapy plus carboplatin group, 51 percent those in the chemotherapy plus Avastin group, and 61 percent of those in the chemotherapy plus carboplatin and Avastin group.

Promising as the results are, "more research is needed to determine which women with triple-negative breast cancer particularly benefit from added carboplatin and which do not," says Winer. "As we learn more about triple-negative breast cancer, we'll be better able to determine which set of drugs is most effective for individual patients.

###

The lead author of the study is William Sikov, MD, of Brown University. Co-authors are Donald Berry, PhD, of University of Texas M.D. Anderson Cancer Center; Charles Perou, PhD, and Lisa Carey, MD, of UNC Lineberger Comprehensive Cancer Center, Chapel Hill, N.C.; Baljit Singh, MBBS, MD, of New York University Medical Center; Constance Cirrincione, MD, Alliance Statistical Center, Durham, N.C.; Sara Tolaney, MD, MPH, Mehra Golshan, MD, and Jennifer Bellon, MD, of Dana-Farber; Charles Kuzma, MD, of Southeast Cancer Control Consortium, Winston-Salem, N.C.; Tim Pluard, MD, of Washington University-St. Louis Medical Center; George Somlo, MD, of City of Hope Comprehensive Cancer Center; Elisa Port, MD, of Mount Sinai Medical Center, New York, N.Y.; Deborah Collyar of Patient Advocates in Research, Danville, Calif.; Olwen Hahn, MD, of University of Chicago Medical Center; and Clifford Hudis, MD, of Memorial Sloan-Kettering Cancer Center.

http://www.eurekalert.org/pub_releases/2013-12/dci-ads120613.php#.UqtrghRjhhk.scoopit



Edited by 123Donna - Dec 14 2013 at 12:10pm
DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09)
11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15

Back to Top
123Donna View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 24 2009
Location: St. Louis, MO
Status: Offline
Points: 12573
Post Options Post Options   Thanks (0) Thanks(0)   Quote 123Donna Quote  Post ReplyReply Direct Link To This Post Posted: Dec 13 2013 at 8:46pm

Carboplatin Yes, Bevacizumab No for Triple-Negative Breast Cancer

SAN ANTONIO — Adding carboplatin to paclitaxel in the neoadjuvant setting for triple-negative breast cancer significantly improves pathologic complete response (pCR) rates. So, for that matter, does adding bevacizumab (Avastin) — somewhat.

The catch is that bevacizumab adds only an incremental benefit, does not have synergistic activity with carboplatin, and is associated with significantly increased toxicities that could outweigh the benefit, said William M. Sikov, MD, from the Warren Alpert Medical School of Brown University in Providence, Rhode Island.

"Should carboplatin be routinely added to stage II or III triple-negative breast cancer? With the caveat...that we do not have long-term results — I think if you're looking in the neoadjuvant setting, my answer to that question would be yes," Dr. Sikov said in a media briefing prior to his presentation.

He explained that carboplatin improved the pCR rate, but it is not known if that will result in significant improvement in recurrence-free or overall survival.

Although bevacizumab also increased the pCR rate, it came "at the cost of significant toxicities, and I don't think it should be routinely added to neoadjuvant chemotherapy," he said.

Jeffrey B. Smerage, MD, PhD, a breast cancer specialist from the University of Michigan Comprehensive Cancer Center in Ann Arbor, who was not involved in the study, told Medscape Medical News that "Dr. Sikov's comments make a lot of sense to me."

He noted that the addition of carboplatin to a standard neoadjuvant regimen "clearly" showed evidence of an increase in pCR.

Even without long-term data, the results are helpful to clinicians, he suggested.

Dr. Smerage explained that in the neoadjuvant setting, patients tend to have larger tumors, often have clinically positive lymph nodes, and generally have higher risks at baseline.

"It's also a setting in which your goal is response. Maybe the goal is to allow a more effective surgery, even if the surgery is going to be a mastectomy.... Maybe your goal is to be able to attempt a lumpectomy, where the goal of that therapy is response but not necessarily prolonged progression-free survival," he said.

Tough Nut to Crack

Triple-negative breast cancers — so called because they lack the drug targets of estrogen, progesterone, and HER2 receptors — comprise approximately 20% of breast cancers, and are more common in blacks, Hispanics, younger women, and those with BRCA1 mutations.

Although there have been advances in chemotherapy in the adjuvant setting, patients with triple-negative disease still have worse prognoses than patients with either estrogen-receptor-positive orHER2-positive tumors. Median overall survival for patients with advanced triple-negative cancers is less than 1 year, Dr. Sikov said.

In the neoadjuvant setting, evidence of a benefit in women with triple-negative disease comes from a meta-analysis presented at last year's SABCS (abstract S1-11). That study showed that 34% of patients had a pCR with neoadjuvant chemotherapy and a better clinical course than women with similar tumors who had residual disease going to surgery.

Dr. Sikov's team chose to study carboplatin for 2 reasons: its activity in patients with BRCA mutation-related cancers, which are similar to sporadic triple-negative cancers in several respects; and the high pCR rates in pilot studies in which carboplatin was added to standard chemotherapy in patients with triple-negative tumors.

2 × 2 Design

The CALGB 40603 study was a randomized phase 2 trial with a 2 × 2 randomization scheme in which all patients received paclitaxel 80 mg/m² weekly for 12 weeks, plus 1 of 3 treatments: bevacizumab 10 mg/kg every 2 weeks for 9 cycles; carboplatin to the area under the curve (AUC) 6 every 3 weeks for 4 cycles; or both carboplatin and bevacizumab.

All patients went on to dose-dense chemotherapy with doxorubicin and cyclophosphamide for 4 cycles.

The trial was designed to look at pCR rates in the breast and axilla, but was not powered to compare individual treatment groups or to detect differences in recurrence-free or overall survival, Dr. Sikov noted.

A total of 443 patients were enrolled, and 427 went on to surgery and were included in the pCR analysis. (Dr. Sikov explained that progression-free and overall survival will be reported at a later date.)

Rates of pCR in the breast were lower in patients who did not receive carboplatin than in those who did (46% vs 60%). The odds ratio (OR) for carboplatin was 1.76 (P = .001).

Rates of pCR in the breast were also lower in patients who did not receive bevacizumab than in those who did (48% vs 59%). The OR for the angiogenesis inhibitor was 1.58 (P = .0089).

However, there was no evidence of a synergistic interaction between the carboplatin and bevacizumab, the investigators found.

Looking at pCR in the breast and axillary lymph nodes, they again saw an effect on pCR in women treated with carboplatin, compared with those who were not (41% vs 54%). The OR for carboplatin in the breast/axilla was 1.71 (= .0029). The same pattern was seen with bevacizumab (44% vs 52%). The OR was 1.36, but it just missed being statistically significant (= .057)

Again, the investigators saw no evidence of synergy in the effect of the drugs on pCR in the breast and axilla combined.

Bevacizumab in this study was also associated with increases in grade 3 toxicities, including hypertension, febrile neutropenia (especially with carboplatin), serious infections despite a normal absolute neutrophil count, bleeding, and thromboembolic and surgical complications.

"We await results of correlative studies, including subtype analysis, to see if we can identify markers of response or resistance to standard neoadjuvant chemotherapy, as well as to the addition of carboplatin or bevacizumab," Dr. Sikov said.

The study was funded by the National Cancer Institute, Genentech, and the Breast Cancer Research Foundation. Dr. Sikov and Dr. Smerage have disclosed no relevant financial relationships.

36th Annual San Antonio Breast Cancer Symposium (SABCS): Abstract S5-01. Presented December 13, 2013.

http://www.medscape.com/viewarticle/817820

DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09)
11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15

Back to Top
123Donna View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 24 2009
Location: St. Louis, MO
Status: Offline
Points: 12573
Post Options Post Options   Thanks (1) Thanks(1)   Quote 123Donna Quote  Post ReplyReply Direct Link To This Post Posted: Jan 11 2014 at 11:31am
Slide Show: 2013 San Antonio Breast Cancer Symposium - See more at: http://www.cancernetwork.com/conference-report/slide-show-2013-san-antonio-breast-cancer-symposium#sthash.qRaAEgHf.4cuysgmV.dpuf

Adding Carboplatin to a Neoadjuvant Chemotherapy Regimen in Triple-Negative Breast Cancer Patients Boosts Pathologic Complete Response Rates

A randomized phase II trial of 454 patients shows that adding both bevacizumab and carboplatin to a standard neoadjuvant chemotherapy backbone increases pathologic complete response (pCR) in patients with triple-negative breast cancer. In the neoadjuvant setting, pCR is associated with improved recurrence-free survival and overall survival. However, bevacizumab also increased high-grade adverse events, including post-surgery complications. The boost in pCR rates when bevacizumab was combined with carboplatin was additive but not synergistic. Patients in the study continue to be followed for long-term recurrence and survival rates.

Source: Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). SABCS 2013; Abstract S5-01.

- See more at: http://www.cancernetwork.com/conference-report/slide-show-2013-san-antonio-breast-cancer-symposium#sthash.qRaAEgHf.4cuysgmV.dpuf



http://www.cancernetwork.com/sabcs-2013/neoadjuvant-combo-effective-triple-negative-breast-cancer
DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09)
11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15

Back to Top
123Donna View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 24 2009
Location: St. Louis, MO
Status: Offline
Points: 12573
Post Options Post Options   Thanks (1) Thanks(1)   Quote 123Donna Quote  Post ReplyReply Direct Link To This Post Posted: Apr 08 2014 at 10:28pm
SABCS 2013 
Better Neoadjuvant Regimens With Carboplatin
Trials show benefit for triple-negative breast cancer

DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09)
11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15

Back to Top
lizziealberta View Drop Down
Newbie
Newbie
Avatar

Joined: Apr 23 2014
Location: Florida
Status: Offline
Points: 17
Post Options Post Options   Thanks (0) Thanks(0)   Quote lizziealberta Quote  Post ReplyReply Direct Link To This Post Posted: Apr 23 2014 at 2:03am
Has anyone on this forum had this therapy. I am in process of deciding on chemo so could use the input. Thank much!
ER+ misdiagnosed 09, was ER+/TNBC,lumpectomy, C/T, rads, AI. TNBC in node 4/14, in neoadjuvant A/C then carbo/gemzar, complete path response. double mastectomy.
Back to Top
atlhoosier View Drop Down
Newbie
Newbie
Avatar

Joined: Feb 18 2014
Status: Offline
Points: 39
Post Options Post Options   Thanks (0) Thanks(0)   Quote atlhoosier Quote  Post ReplyReply Direct Link To This Post Posted: Apr 23 2014 at 2:01pm
I am currently undergoing taxol & carboplatin.  I've had 8 doses of taxol and 3 of carboplatin.  I have 1 more treatment of carbo and 4 of the taxol.  Then I will have 4 treatments of A/C.  

Next Friday I will have a mammogram to see the progress.  I'll be sure to let you know!

PS...I'm sorry your dog died the same day!  :(
DX Jan 2014, 37yo
stage 2a, grade 3
TN, 4 tumors in LB, 0 in RB
Back to Top
123Donna View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 24 2009
Location: St. Louis, MO
Status: Offline
Points: 12573
Post Options Post Options   Thanks (1) Thanks(1)   Quote 123Donna Quote  Post ReplyReply Direct Link To This Post Posted: May 14 2014 at 9:10pm
New way to predict response to chemo in triple-negative breast cancer
Researchers from University Hospitals (UH) Case Medical Center's Seidman Cancer Center will present findings from a study that found the presence of tumor-infiltrating lymphocytes, a type of white blood cell, ahead of treatment may help predict response to platinum-based chemotherapy in women with triple-negative breast cancer. The data are being presented at the 50th American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago.

"Triple-negative breast cancers tend to be more aggressive compared to other types of breast cancers, and being able to predict response to therapy could greatly impact treatment decisions and patient outcomes," says study author Shaveta Vinayak, MD, oncologist at UH Case Medical Center and Assistant Professor at Case Western Reserve University School of Medicine. "Our research shows that the presence of lymphocytesbefore administering chemotherapy could predict a positive response to platinum-based therapy."

Triple negative breast cancers are those that do not have estrogen or progesterone receptors, and do not have an excess of the HER2 protein on the cancer cell surfaces. This makes it more difficult to treat because the hormone-blocking or the HER2-targeting treatments do not work. Triple negative breast cancers tend to occur more often in younger women and in African-American women.

Platinum-based therapies are being tested in clinical trials for triple-negative breast cancer, and evaluation of tumor-infiltrating lymphocytes is an important factor in determining response to this treatment. For oncologists, this could provide a new tool to individualize treatment for these women.

Researchers from various institutions in the Eastern Cooperative Oncology Group, one of the largest clinical cancer research organizations in the United States that conducts clinical trials in all types of adult cancers, contributed to this analysis. Funding for this study was provided by Breast Cancer Research Foundation, ASCO Conquer Cancer Foundation, Triple-Negative Breast Cancer Foundation, Myriad Genetics, and National Institutes of Health (Stanford CTSA).

About the Study

Oral Abstract Session

Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy

Abstract #1024: June 3, 9:45 AM - 12:45 PM

Dr. Vinayak will present new findings from the PrECOG 0105 trial, a trial evaluating neoadjuvant platinum-based chemotherapies – carboplatin, gemcitabine and iniparib – in women with triple-negative breast cancer. This correlative study assessed the association of tumor-infiltrating lymphocytes in pre-treatment breast cancer tissue with pathologic response to treatment.

The trial evaluated 70 patients with triple-negative breast cancer who had completed at least 4 of 6 planned cycles of therapy. Tissue and tumor sections from pre-chemotherapy biopsies were evaluated by a central pathologist for density of lymphocytes. Pathologic response was assessed by the residual cancer burden index.

Results showed that tumor-infiltrating lymphocytes found in the connective tissue and the tumor itself are predictive of response to platinum-based neoadjuvant chemotherapy and are significantly associated with triple-negative breast cancersubtypes, with the highest frequency in the immunomodulatory subtype.

http://medicalxpress.com/news/2014-05-response-chemo-triple-negative-breast-cancer.html


DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09)
11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15

Back to Top
mimsey View Drop Down
Newbie
Newbie
Avatar

Joined: May 01 2014
Location: United States
Status: Offline
Points: 4
Post Options Post Options   Thanks (0) Thanks(0)   Quote mimsey Quote  Post ReplyReply Direct Link To This Post Posted: May 15 2014 at 5:47pm
Mastectomy  Feb
I am having Carboplatin right now ..with Taxol....
Followed by  A/C
Than radiation 
Back to Top
MomMom44 View Drop Down
Senior Member
Senior Member
Avatar

Joined: Apr 27 2014
Location: Alexandria, VA
Status: Offline
Points: 138
Post Options Post Options   Thanks (1) Thanks(1)   Quote MomMom44 Quote  Post ReplyReply Direct Link To This Post Posted: May 16 2014 at 3:51pm
Mimsey,
 
Welcome to the thread.  What is your diagnosis?  My MO initially suggested that she might add Carboplatin to the Taxol, but decided later it wasn't necessary.  As you can see from my signature, I've completed 4 DD AC and yesterday had my third of 12 weekly Taxol.
 
Are you finding the Carbo & Taxol to be tolerable?
 
 
DX TNBC 1/14; age 66; Stage 1; Grade 2; 1.2 cm; 0/2 nodes; lumpectomy; BRAC Neg; 4 DD AC; Completed 12 weekly Taxol July 2014; Radiation August 2014
Back to Top
123Donna View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 24 2009
Location: St. Louis, MO
Status: Offline
Points: 12573
Post Options Post Options   Thanks (0) Thanks(0)   Quote 123Donna Quote  Post ReplyReply Direct Link To This Post Posted: Jun 30 2014 at 5:03pm
Bumping for new members
DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09)
11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15

Back to Top
rosewater View Drop Down
Senior Member
Senior Member
Avatar

Joined: Jun 30 2014
Location: Vancouver, B.C.
Status: Offline
Points: 127
Post Options Post Options   Thanks (0) Thanks(0)   Quote rosewater Quote  Post ReplyReply Direct Link To This Post Posted: Jul 01 2014 at 2:08am
Many thanks to you, Donna, for bringing this thread to my attention.

Mimsey, I too am curious to hear more about how treatment with Taxol and Carboplatin has been for you. I'm also interested in how you came to the decision to add Carboplatin. My oncologist is considering adding it for me as well (in 3 weeks), but in the adjuvant setting, rather than in the neoadjuvant setting (as with the clinical trials).

I'm curious if anyone else has tried this drug yet, and if anyone has tried it in the adjuvant setting??

Thank you!
rosewater
DX IDC TNBC 03/14 age 40, Stage 1, Grade 3, 2cm, 0/4Nodes, lumpectomy 04/14, DD A/C x4, Taxol x12, Carboplatin x2, BMX 10/14, rads x28 Finished Jan 14/15, Oopherectomy Jan 29/15 BRCA 2+
Back to Top
123Donna View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 24 2009
Location: St. Louis, MO
Status: Offline
Points: 12573
Post Options Post Options   Thanks (0) Thanks(0)   Quote 123Donna Quote  Post ReplyReply Direct Link To This Post Posted: Jul 01 2014 at 8:25am
Rosewater,

This may or may not help with the information you are asking.  I did not have Carbo for my initial treatment in 2009.  When I had my recurrence in 2010, I entered a clinical trial that included Carboplatin and Gemzar with a trial drug.  The internal mammary node was not removed surgically so we hoped the drugs would do their job in an adjuvant setting.  After 2 rounds, the scan showed no evidence of disease.  I went on to have 2 more rounds then 40 rounds of radiation.  

Donna
DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09)
11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15

Back to Top
littleradish View Drop Down
Groupie
Groupie


Joined: Nov 02 2013
Location: California
Status: Offline
Points: 41
Post Options Post Options   Thanks (0) Thanks(0)   Quote littleradish Quote  Post ReplyReply Direct Link To This Post Posted: Jul 01 2014 at 3:21pm
Rosewater

I had TC neo-adjuvant and after my mastectomy they still found 50% of the tumor. We thought it was gone but apparently it became like swiss cheese and could not be seen on ultrasound so they suggested more chemo.
I was given cisplatin and gemzar in the adjuvant setting.

Diagnosed March 2013, TC chemo from April-July 4 rounds. Double mastectomy Aug of 2013 clear margins and no lymph nodes involved. 4 rounds of gemzar and cisplatin September to October
Back to Top
rosewater View Drop Down
Senior Member
Senior Member
Avatar

Joined: Jun 30 2014
Location: Vancouver, B.C.
Status: Offline
Points: 127
Post Options Post Options   Thanks (0) Thanks(0)   Quote rosewater Quote  Post ReplyReply Direct Link To This Post Posted: Jul 01 2014 at 3:28pm
Thank you, Donna and littleradish!

It's sooo interesting how everyone reacts to these drugs!!


DX IDC TNBC 03/14 age 40, Stage 1, Grade 3, 2cm, 0/4Nodes, lumpectomy 04/14, DD A/C x4, Taxol x12, Carboplatin x2, BMX 10/14, rads x28 Finished Jan 14/15, Oopherectomy Jan 29/15 BRCA 2+
Back to Top
Lillie View Drop Down
Senior Member
Senior Member
Avatar

Joined: Jul 10 2009
Location: Eastern NC
Status: Offline
Points: 3586
Post Options Post Options   Thanks (0) Thanks(0)   Quote Lillie Quote  Post ReplyReply Direct Link To This Post Posted: Jul 01 2014 at 7:40pm
Hi Rosewater,
I did an adjuvant clinical trial of Dose Dense Cytoxan and Adriamician(sp)x 4 followed by Dose Dense Taxol and Gemzar x 4. Since I had a mastectomy first, no radiation was done. I did have micromets in 1 lymph node which was removed when I had the mastectomy.

I think there is something about getting the cisplatin, carboplatin or gemzar that can be a good thing.

Just my opinion.

God Bless,
Lillie
Dx 6/06 age 65,IDC-TNBC
Stage IIb,Gr3,2cm,BRCA-
6/06 L/Mast/w/SNB,1of3 Nodes+
6/06 Axl. 9 nodes-
8/8 thru 11/15 Chemo (Clin-Trial) DD A/Cx4 -- DD taxol+gemzar x4
No Rads.
No RECON - 11/2015-9 yrs NED
Back to Top
JackiWalkr View Drop Down
Groupie
Groupie
Avatar

Joined: Jun 25 2014
Location: California
Status: Offline
Points: 59
Post Options Post Options   Thanks (0) Thanks(0)   Quote JackiWalkr Quote  Post ReplyReply Direct Link To This Post Posted: Jul 02 2014 at 12:50pm
I am currently taking Carboplatin and Taxol. I had 1 treatment of the combo and we can't feel lump anymore. Since then I have had 2 more combo's and 1 Taxol. I have been postponed 1 week due to low liver levels from Taxol and 4 weeks due to low neutrophils from Carboplatin. Even had blood transfusion with 2 bags. I am back on schedule with modified doses and extra week of recovery. I have 1 Carboplatin/Taxol combo left and 7 Taxol doses. Modified dose of 600 mg Carbo and 100mg Taxol was a breeze compared to first dose of 714 mg Carbo and 134 mg Taxol.

Jackie
DX IDC TNBC 3/31/14 Age 46 Stage 2a, Grade 3, 2.1cm, 0 nodes, (4)Carbo(5)Taxol. AC DD 4 of 4. Lumpectomy 10/30/2014 NED. 33 Rads 2/12/15. BRCA 1/2 normal=negative
Back to Top
sweetjam View Drop Down
Groupie
Groupie
Avatar

Joined: Jan 24 2014
Location: Arizona
Status: Offline
Points: 44
Post Options Post Options   Thanks (0) Thanks(0)   Quote sweetjam Quote  Post ReplyReply Direct Link To This Post Posted: Jul 06 2014 at 5:17pm
I had 6 treatments of carboplatin and taxol every 3 weeks. My tumor initially grew after 2 rounds or sometime before I started chemo. They told me the tumor still had 10% cancer in it when they took it out. Just hoping the chemo has done its job. There has been no talk of rads because I had both breast removed.
DX 1/17/14 TN IDC, Stage 1 Grade 2, 1.4cm, Age 50, BRCA -, Started Chemo 2/10 C/T, every 3 weeks. Last Chemo 5/23/14. Double Mastectomy 6/23 3/4 nodes all negative. 6/23 final path tumor ER+, PR+,
Back to Top
JMJ View Drop Down
Newbie
Newbie
Avatar

Joined: May 27 2014
Status: Offline
Points: 31
Post Options Post Options   Thanks (1) Thanks(1)   Quote JMJ Quote  Post ReplyReply Direct Link To This Post Posted: Jul 08 2014 at 5:16pm
I had 4 doses AC followed by 12 weeks of taxol and carboplatin every 3 weeks. I have one more carbo to go and 5 more taxols. I skipped one week of taxol due to low WBC count the week after my second taxol/carbo they added the taxol I missed onto the end of treatment. I had my mastectomy first but had I gone to the facility I am receiving treatment at first, they would have had me do chemo first. I transferred care after my unilateral mastectomy. I started chemo within 30 days of surgery though and my dr added lupron shots every 4 weeks. I had 3 positive lymph nodes. The 3rd node was considered micromets. I will have rads because my tumor was 4.6 cm and my smallest margin was less than a mm. I also had lymph vascular invasion and necrosis.

I have tolerated everything well, I had some nausea with the AC and am more tired with the taxol/carbo. I had one week my platelets were boarder line, that was the week before my WBC count was too low. I have had some neuropathy in my feet with the carbo/taxol. I am taking L-glutamine and B6 to help with that, other supplements they are having me take are calcium and vit D. My initial vit D was 18. I should mention for me the hardest part has been the chemo brain.

I hope everyone is doing well!
+JMJ+
Back to Top
tmariee View Drop Down
Newbie
Newbie
Avatar

Joined: Jul 22 2014
Location: NW Indiana
Status: Offline
Points: 2
Post Options Post Options   Thanks (0) Thanks(0)   Quote tmariee Quote  Post ReplyReply Direct Link To This Post Posted: Jul 22 2014 at 6:10pm
Hi everybody!  I just joined the forum, having completed 4 rounds of AC and 10 rounds of Taxol plus Carboplatin for TNBC.  I was diagnosed in Dec of 2013, lumpectomy 1/6/14, followed by brachytherapy (SAVI) two weeks later.  I did 4 rounds of AC starting 2/21/14, and then added Carboplatin to the 12 weekly rounds of Taxol that was to follow.  We knew that adding the Carbo may increase the efficacy of treatment, but also may increase the stress on my bone marrow.  After round 10 my platelet count dropped such that I couldn't do another infusion,  and remained too low for 3 more weeks.  At that point (last week) my Oncologist decided that my bone marrow has had enough and told me that I'm done with chemo.  I asked about the consequences of doing 10 instead of 12 rounds, and he told me that the newest research indicates that the Carboplatin may be just as or more important than the Taxol, and that I had done a LOT of chemo.  My last infusion was 4 weeks ago.  I'm starting to regain my energy (in baby steps), and I'm also starting to see some hair sprout on my noggin. 

My tumor was stage 2 (just over 2 cm), grade 3, with clean margins and with 0/4 lymph nodes affected.  They found it on my yearly mammo; I had no symptoms and didn't feel anything until I knew it was there.  

I've recently read about a promising clinical trial at MD Anderson for a vaccine to prevent recurrence.  Anybody know anything about this?  I've put in a message to my Onco doc inquiring about it this morning.
Back to Top
Linda428 View Drop Down
Newbie
Newbie
Avatar

Joined: Jan 08 2014
Location: Texas
Status: Offline
Points: 37
Post Options Post Options   Thanks (0) Thanks(0)   Quote Linda428 Quote  Post ReplyReply Direct Link To This Post Posted: Jul 22 2014 at 6:54pm
X

Edited by Linda428 - Jul 22 2014 at 6:56pm
Back to Top
 Post Reply Post Reply Page  12>
  Share Topic   

Forum Jump Forum Permissions View Drop Down

Forum Software by Web Wiz Forums® version 11.05
Copyright ©2001-2016 Web Wiz Ltd.